AR114032A2 - 5-(3,4-dicloro-fenil)-n-(2-hidroxi-ciclohexil)-6-(2,2,2-trifluor-etoxi)-nicotinamida y sales de la misma - Google Patents
5-(3,4-dicloro-fenil)-n-(2-hidroxi-ciclohexil)-6-(2,2,2-trifluor-etoxi)-nicotinamida y sales de la mismaInfo
- Publication number
- AR114032A2 AR114032A2 ARP180103371A ARP180103371A AR114032A2 AR 114032 A2 AR114032 A2 AR 114032A2 AR P180103371 A ARP180103371 A AR P180103371A AR P180103371 A ARP180103371 A AR P180103371A AR 114032 A2 AR114032 A2 AR 114032A2
- Authority
- AR
- Argentina
- Prior art keywords
- salts
- etoxy
- trifluor
- nicotinamide
- dichloro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
La presente se refiere a un compuesto de la fórmula (1), en todas sus formas isómeras y las sales farmacéuticamente aceptables del mismo, a su obtención, a las composiciones farmacéuticas que lo contienen y a su utilización como medicamento para el tratamiento y/o profilaxis de enfermedades que pueden tratarse con agentes que elevan el colesterol HDL, como son con preferencia la dislipidemia, la aterosclerosis y las enfermedades cardiovasculares. Reivindicación 1: Un compuesto de la fórmula (1), las formas isómeras y las sales farmacéuticamente aceptables del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09170097 | 2009-09-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR114032A2 true AR114032A2 (es) | 2020-07-15 |
Family
ID=42830122
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100103303A AR078352A1 (es) | 2009-09-11 | 2010-09-09 | 5-(3,4-dicloro-fenil) -n- (2-hidroxi - ciclohexil) -6- (2,2,2 -trifluor-etoxi) nicotinamida y sales de la misma |
ARP180103371A AR114032A2 (es) | 2009-09-11 | 2018-11-16 | 5-(3,4-dicloro-fenil)-n-(2-hidroxi-ciclohexil)-6-(2,2,2-trifluor-etoxi)-nicotinamida y sales de la misma |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100103303A AR078352A1 (es) | 2009-09-11 | 2010-09-09 | 5-(3,4-dicloro-fenil) -n- (2-hidroxi - ciclohexil) -6- (2,2,2 -trifluor-etoxi) nicotinamida y sales de la misma |
Country Status (35)
Country | Link |
---|---|
US (1) | US8227491B2 (es) |
EP (1) | EP2475645B1 (es) |
JP (1) | JP5604520B2 (es) |
KR (1) | KR101382871B1 (es) |
CN (1) | CN102639506B (es) |
AR (2) | AR078352A1 (es) |
AU (1) | AU2010294277B2 (es) |
BR (1) | BR112012005511B8 (es) |
CA (1) | CA2771493C (es) |
CL (1) | CL2012000611A1 (es) |
CO (1) | CO6491033A2 (es) |
CR (1) | CR20120089A (es) |
CY (1) | CY1114377T1 (es) |
DK (1) | DK2475645T3 (es) |
EC (1) | ECSP12011723A (es) |
ES (1) | ES2423821T3 (es) |
HK (1) | HK1172021A1 (es) |
HR (1) | HRP20130869T1 (es) |
IL (1) | IL217920A (es) |
IN (1) | IN2012DN00763A (es) |
MA (1) | MA33563B1 (es) |
MX (1) | MX2012002254A (es) |
MY (1) | MY161103A (es) |
NZ (1) | NZ597514A (es) |
PE (1) | PE20120863A1 (es) |
PL (1) | PL2475645T3 (es) |
PT (1) | PT2475645E (es) |
RS (1) | RS52987B (es) |
RU (1) | RU2541475C2 (es) |
SG (1) | SG179035A1 (es) |
SI (1) | SI2475645T1 (es) |
TW (1) | TWI412363B (es) |
UA (1) | UA107088C2 (es) |
WO (1) | WO2011029827A1 (es) |
ZA (1) | ZA201201599B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012031817A1 (en) * | 2010-09-09 | 2012-03-15 | F. Hoffmann-La Roche Ag | Determination of abca1 protein levels in cells |
US8410107B2 (en) | 2010-10-15 | 2013-04-02 | Hoffmann-La Roche Inc. | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides |
US20120101282A1 (en) * | 2010-10-22 | 2012-04-26 | Pascal Dott | Process for the preparation of nicotinamide derivatives |
US8669254B2 (en) | 2010-12-15 | 2014-03-11 | Hoffman-La Roche Inc. | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents |
WO2014180741A1 (en) * | 2013-05-06 | 2014-11-13 | F. Hoffmann-La Roche Ag | Methods of identifying modulators of osbpl7 and the use of such modulators for treatment of diseases associated with osbpl7 |
US20200085810A1 (en) | 2018-07-26 | 2020-03-19 | Hoffmann-La Roche Inc. | Compounds for use in treating kidney disorders |
US11814354B2 (en) * | 2021-09-08 | 2023-11-14 | River 3 Renal Corp. | Solid forms |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI259180B (en) * | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
MX2007012213A (es) * | 2005-04-06 | 2007-12-10 | Hoffmann La Roche | Derivados de piridin-3-carboxamida como agonistas inversos de canabinoides. |
KR101107896B1 (ko) * | 2006-10-04 | 2012-01-25 | 에프. 호프만-라 로슈 아게 | 고 밀도 지단백질(hdl)-콜레스테롤 상승제로서 3-피리딘카복스아마이드 및 2-피라진카복스아마이드 유도체 |
-
2010
- 2010-08-09 UA UAA201204339A patent/UA107088C2/ru unknown
- 2010-09-03 US US12/875,196 patent/US8227491B2/en active Active
- 2010-09-08 TW TW099130367A patent/TWI412363B/zh active
- 2010-09-08 NZ NZ597514A patent/NZ597514A/xx unknown
- 2010-09-08 KR KR1020127008704A patent/KR101382871B1/ko active IP Right Grant
- 2010-09-08 SG SG2012016127A patent/SG179035A1/en unknown
- 2010-09-08 MX MX2012002254A patent/MX2012002254A/es active IP Right Grant
- 2010-09-08 WO PCT/EP2010/063136 patent/WO2011029827A1/en active Application Filing
- 2010-09-08 AU AU2010294277A patent/AU2010294277B2/en active Active
- 2010-09-08 PE PE2012000302A patent/PE20120863A1/es active IP Right Grant
- 2010-09-08 CA CA2771493A patent/CA2771493C/en active Active
- 2010-09-08 DK DK10749873.5T patent/DK2475645T3/da active
- 2010-09-08 PT PT107498735T patent/PT2475645E/pt unknown
- 2010-09-08 IN IN763DEN2012 patent/IN2012DN00763A/en unknown
- 2010-09-08 BR BR112012005511A patent/BR112012005511B8/pt active IP Right Grant
- 2010-09-08 RU RU2012113924/04A patent/RU2541475C2/ru active
- 2010-09-08 MY MYPI2012001104A patent/MY161103A/en unknown
- 2010-09-08 JP JP2012528344A patent/JP5604520B2/ja active Active
- 2010-09-08 EP EP10749873.5A patent/EP2475645B1/en active Active
- 2010-09-08 ES ES10749873T patent/ES2423821T3/es active Active
- 2010-09-08 PL PL10749873T patent/PL2475645T3/pl unknown
- 2010-09-08 SI SI201030327T patent/SI2475645T1/sl unknown
- 2010-09-08 CN CN201080039932.7A patent/CN102639506B/zh active Active
- 2010-09-08 RS RS20130395A patent/RS52987B/en unknown
- 2010-09-09 AR ARP100103303A patent/AR078352A1/es not_active Application Discontinuation
-
2012
- 2012-01-12 CO CO12004250A patent/CO6491033A2/es active IP Right Grant
- 2012-02-02 IL IL217920A patent/IL217920A/en active IP Right Grant
- 2012-02-21 CR CR20120089A patent/CR20120089A/es unknown
- 2012-03-02 ZA ZA2012/01599A patent/ZA201201599B/en unknown
- 2012-03-03 EC ECSP12011723 patent/ECSP12011723A/es unknown
- 2012-03-05 MA MA34662A patent/MA33563B1/fr unknown
- 2012-03-08 CL CL2012000611A patent/CL2012000611A1/es unknown
- 2012-12-12 HK HK12112824.3A patent/HK1172021A1/xx unknown
-
2013
- 2013-09-05 CY CY20131100768T patent/CY1114377T1/el unknown
- 2013-09-16 HR HRP20130869AT patent/HRP20130869T1/hr unknown
-
2018
- 2018-11-16 AR ARP180103371A patent/AR114032A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR114032A2 (es) | 5-(3,4-dicloro-fenil)-n-(2-hidroxi-ciclohexil)-6-(2,2,2-trifluor-etoxi)-nicotinamida y sales de la misma | |
AR093247A1 (es) | Agente profilactico y/o terapeutico para sintomas conductuales y psicologicos asociados con la enfermedad neurodegenerativa o sintomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo | |
CR20160237A (es) | Derivados de la carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
CL2013003472A1 (es) | Compuestos derivados de halogenoalquil-1,3-oxazinas sustituidas, inhibidores de la bace1 y/o bace2; procedimiento de obtencion; composicion farmaceutica que los comprende; su uso en el tratamiento y/o profilaxis de enfermedades tales como diabetes, alzheimer, als, enfermedades autoinmunes inflamatorias, cancer, entre otras. | |
CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
TR201904455T4 (tr) | Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları. | |
DOP2011000279A (es) | Derivados de benzofuranilo usados como inhibidores de glucoquinasa | |
UY32793A (es) | Compuestos inhibidores de los virus flaviviridae, composición farmacéutica que los contiene y sus usos | |
CO6491060A2 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
CL2011002359A1 (es) | Compuesto atropisomero opticamente activo de 2-(((6-amino-9h-purin-9il)metil)-5-metil-3-o-tolilquinazolin-4(3h)-ona, inhibidor de las isoformas pdk, particularmente la isoforma delta; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer, rinitis, alergica, asma, dermatitis atopica, entre otras. | |
IN2015DN00376A (es) | ||
PE20121617A1 (es) | Derivados de oxazina como inhibidores de bace | |
AR084932A1 (es) | Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica | |
PH12014501693A1 (en) | Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof | |
CR20130264A (es) | Compuestos pirimidinona para uso en el tratamiento de enfermedades o condiciones mediadas por lp-pla2 | |
BR112013005622A2 (pt) | heteroaril metil amidas | |
UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
CL2013001591A1 (es) | Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades. | |
EA201591541A1 (ru) | Ингибиторы бета-секретазы 1 (bace 1) | |
GT201400288A (es) | "compuestos de fenoxietil piperidina" | |
CO7151509A2 (es) | Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1 | |
GB2523707A (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
UY33530A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias | |
PE20151607A1 (es) | Formulaciones de compuestos organicos | |
AR083095A1 (es) | Cocristal de aprepitant l-prolina y composicion farmaceutica |